Simethicone Pharma Grade API is supplied as powder model SIM-P100 and emulsion model SIM-E30. The powder is a compendial mixture of polydimethylsiloxane and finely divided silicon dioxide containing 90.5–99.0% polydimethylsiloxane and 4.0–7.0% silicon dioxide. The emulsion contains 25.0–35.0% simethicone according to the USP-NF Simethicone Emulsion monograph. Unlike polydimethylsiloxane fluid alone, the silica component provides particulate hydrophobic film-breakage nuclei, which differentiates simethicone from dimeticone and from non-compendial silicone antifoam fluids. Solid oral dosage forms and granules are generally produced from the powder; aqueous liquids, wet-granulation binder sprays, and oral liquid compounding use the emulsion. Injectable applications require additional qualification because no harmonized parenteral monograph exists for simethicone, and such development falls outside routine oral compendial release testing.

The compendial silicon dioxide range is functionally significant. Below 4.0% silicon dioxide, the number of effective hydrophobic breakage points per unit volume is insufficient for rapid foam collapse. Above 7.0% silicon dioxide, silica agglomeration increases bulk viscosity and reduces spreadability across the gas–liquid interface. Incoming release should therefore include assay, silicon dioxide content, loss on drying, and dispersion quality rather than assay alone. The powder grade is intended for dry blending, slugging, and dry granulation; the emulsion grade is intended for aqueous dispersion, wet granulation, spray coating, and oral liquid manufacture. This distinction is not merely physical form but determines the processing route and the critical process parameters required for content uniformity.

How Should the Powder and Emulsion Models Be Handled in Solid Oral Dosage Manufacturing?

For tablet production, SIM-P100 is introduced as an intragranular dry blend component in a bin blender operated at 12–18 rpm for 10–15 minutes with microcrystalline cellulose, dibasic calcium phosphate dihydrate, crospovidone, and reduced magnesium stearate. The hydrophobic silica contributes lubricity; total magnesium stearate can be reduced by 0.25–0.5% without increasing ejection force on a rotary tablet press using 8–10 mm tooling. Content uniformity is assessed by USP 905. Tablets containing 20–125 mg simethicone per unit are common in oral formulations, but above 30% w/w the blend frequently shifts to poor flow and slugging or roller compaction is required rather than direct compression. When the powder is included above 30% w/w, the silicone phase tends to cold-flow under compression, causing weight variability on high-speed presses. Slugs are milled through a 1.5 mm screen and recompressed with extragranular disintegrant and glidant; ribbon density or slug hardness is monitored and held within ±10% of the approved value to preserve friability and dissolution behavior.

For capsule filling, SIM-P100 is compatible with dosator and tamping-pin machines, but the powder’s low bulk density and electrostatic charge require relative humidity control between 40% and 50% RH. On a tamping-pin capsule machine with a forced feeder, stationary powder zones can develop when hopper fill falls below 20% volume. Fill weight variability is reduced by maintaining hopper fill above 50% volume and by adding 0.5–1.0% fumed silica flow conditioner when the simethicone content exceeds 15% w/w. For dosator-type machines, pin compression is adjusted to avoid over-compressing the waxy powder; the polydimethylsiloxane phase can cold-flow and cause inconsistent slug retention. Capsule content uniformity is verified by USP 905, and the powder should pass a 600 µm screen before use to remove soft agglomerates.

Wet granulation preferably uses the emulsion model rather than the powder. In a 300 L high-shear granulator operating at an impeller tip speed of 5–8 m/s, SIM-E30 is sprayed through a 0.8 mm nozzle at 0.5–1.0 bar atomising pressure. Binder addition is stopped when torque increases by 10–15% above the dry-mix baseline. The granulate is dried in a fluid-bed dryer with inlet air temperature 50–60 °C to loss on drying below 2.0% by USP 731, then milled through a 1.0 mm conical mill at 1,000–1,500 rpm. If the powder grade is used in wet granulation, it must first be dispersed in a binder solution or dry-blended before aqueous addition to avoid local hydrophobic clumping and uneven distribution of silica.

For oral liquids, SIM-E30 is added to the aqueous phase after pH adjustment to 4.0–6.0. A rotor-stator mixer at 3,000–5,000 rpm for 10–15 minutes prevents creaming; droplet size is verified by laser diffraction per ISO 13320-1:2020 and should not show a D50 increase greater than 25% after 24 h at 25 °C. Compared with non-compendial 10% or 15% simethicone emulsions, the 30% emulsion reduces water and preservative load but requires positive-displacement pumping because its viscosity is higher and air entrainment occurs more readily with centrifugal transfer.

Defoaming Activity, Silica Dispersion, and Bubble Film Rupture

Polydimethylsiloxane lowers surface tension to approximately 20 mN/m; however, surface tension reduction alone is not the primary mechanism of simethicone defoaming. The hydrophobic silica particles act as film-breakage nuclei. When a foam lamella thins to approximately 50–100 nm, the particle surface creates a dewetting discontinuity that ruptures the liquid film. The compendial silicon dioxide range of 4.0–7.0% is bounded on both sides: below 4.0% particle density is insufficient, and above 7.0% the silica forms larger agglomerates that increase viscosity and reduce the spreading rate over the foam interface. Defoaming activity is therefore not linear with silica content; the upper limit is set by dispersion quality as much as by chemical composition.

For incoming material, silica surface area is measured by BET nitrogen adsorption per ISO 9277:2022; fumed silica grades used in pharmaceutical simethicone typically show surface areas between 200 m²/g and 350 m²/g. Hydrophobisation is controlled by the manufacturer, because residual surface silanol groups cause batch-to-batch shifts in defoaming performance. Laser diffraction per ISO 13320-1:2020 in a non-polar dispersant is used to quantify agglomerates. A powder D90 above 150 µm suggests moisture uptake or incomplete destructuring and should trigger rejection or reprocessing through a 600 µm screen before blending. In a ribbon blender with chopper speed 1,500 rpm, soft agglomerates are broken by screening; hard agglomerates indicate over-humidification or loss of hydrophobic treatment.

The emulsion model must maintain a droplet-size distribution that delivers silica and polydimethylsiloxane together. If phase separation exceeds 5% by volume, defoaming activity becomes non-uniform and the batch should not be released. Emulsion viscosity at 25 °C is controlled by Ph.Eur. 2.2.8 using a rotating viscometer; the system is shear-thinning, so acceptance limits are defined at a fixed shear rate rather than a single-point value. In a 200 L stainless steel vessel with a bottom-mounted agitator, the emulsion should be recirculated with a positive-displacement pump at 50–100 L/min before use, because silicone droplets can cream during static storage and change the assay if sampled from the top. Cavitating centrifugal pumps should be avoided because they can destabilize the emulsion.

Pharmacopoeial Compliance and Specification Limits

The powder and emulsion grades are released under the USP-NF Simethicone and Simethicone Emulsion monographs and Ph.Eur. 1470 where applicable. The table lists release parameters and corresponding test methods for the two model designations.

Residual solvent testing per USP 467 and elemental impurities per USP 232 and USP 233 or ICH Q3D are required at the drug product level unless the API is explicitly controlled. Because simethicone is a silicone polymer, the monograph controls residual low-molecular-weight siloxanes; these are not equivalent to ICH Q3C residual solvents. The powder grade has low water activity and is suitable for moisture-sensitive formulations; the emulsion grade requires preservative efficacy testing per USP 51 when packaged in multidose oral containers.

Simethicone should not be interchanged with dimeticone Ph.Eur. 0138 in a formula. Dimeticone is a silicone fluid without silica; it lowers surface tension but lacks the solid particle mechanism required for robust foam collapse. Simethicone powder also differs from fumed silica alone because the silica is dispersed in the polydimethylsiloxane phase rather than added as dry powder. Adding fumed silica separately to a formulation does not reproduce the same defoaming activity unless the identical dispersion process is used. Non-compendial antifoam emulsions with lower active content introduce more water, require more preservative, and may use surfactants that interact with capsule shells or granulating binders.

When Injectable-Grade Processing and Compendial Parenteral Requirements Are Applied

Simethicone monographs are not harmonized for parenteral use. An injectable product must therefore be controlled under ICH Q6A and regional parenteral chapters. Sterility per Ph.Eur. 2.6.1, bacterial endotoxin per Ph.Eur. 2.6.14, and sub-visible particulate matter per Ph.Eur. 2.9.19 are required. The hydrophobic polydimethylsiloxane/silica powder is poorly wetted by aqueous media and cannot be terminally sterilised by moist heat without a validated low-water-activity cycle. Terminal sterile filtration of emulsions through 0.22 µm polyethersulfone membranes may blind rapidly because silica agglomerates exceed membrane pore size; filter capacity should be established by a constant-pressure Vmax test before scale-up. Published data for this specific injectable configuration are limited. Strong oxidising agents, amine-based additives, and high-shear cavitation should be avoided during injectable development because these can destabilise the silicone phase or generate particulates. Endotoxin control should be established on the silica source, because endotoxin can adsorb to silica surfaces and may be masked in standard LAL assays; sample preparation should include dispersing agents validated for endotoxin recovery.

Storage and handling of SIM-P100 requires sealed polyethylene-lined drums at 15–25 °C. Exposure to relative humidity above 60% RH may cause silica hydration and a loss of defoaming activity; if exposed, the powder is pre-dried at 40 °C under vacuum for 2 h before use. SIM-E30 should not be frozen; phase separation below 5 °C may not be reversible by stirring. Use stainless steel or glass-lined equipment. Do not combine with amine-based additives or strong oxidising agents in the same blend. Before production use, the emulsion is homogenised and sampled at the tank bottom, middle, and top; the three sampling points should agree within 5% of the assay value before release to the manufacturing line.